ERBB2 and breast cancer: Among patients with commonly aggressive breast cancer subtypes (Luminal B, HER2-positive, and triple-negative), 15 of 49 (30.6%) in Group A1 were diagnosed at stage I, compared with only 11 of 113 (9.7%) in Group B1.